Socionext (6526) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
31 Oct, 2025Executive summary
Net sales for the 6 months ended September 30, 2025, were ¥87.2B, down 12.1% year-over-year, with operating income at ¥3.8B, down 75.8%, and net income at ¥2.1B, down 82.2%.
2Q FY26/3 net sales rose 13.5% year-over-year to ¥52.7B, driven by automotive, but operating income fell 56% to ¥2.3B due to higher product cost ratio and increased R&D.
Product revenue rebounded in 2Q after a weak 1Q, mainly from new automotive mass production, while NRE revenue remained flat or declined.
NRE revenue decreased 12.4% year-over-year, reflecting slower design and development milestones.
The company continues to invest in advanced semiconductor technologies and collaborates with global partners.
Financial highlights
2Q FY26/3 product revenue increased 18.1% year-over-year to ¥44.5B; NRE revenue decreased 5.6% to ¥8.0B.
Product cost ratio rose 10.3 points year-over-year to 69.4%, compressing gross margin; 1H FY26/3 product cost ratio increased to 64.3% from 56.5%.
Operating margin for 2Q FY26/3 was 4.4%, down 7.0 points year-over-year; 1H FY26/3 operating margin was 4.3%.
Cash and cash equivalents at period end were ¥45.7B, down ¥27.2B from March 2025; inventories rose to ¥28.2B.
Gross profit for the period was ¥41.9B, down from ¥54.0B year-over-year.
Outlook and guidance
FY26/3 full-year net sales forecast raised to ¥190.0B (from ¥175.0B), but operating income forecast cut to ¥10.0B (from ¥14.0B) and net income to ¥6.7B.
Despite higher sales, profit guidance was lowered due to gross margin pressure from product mix and delayed cost reductions.
Net income forecast for FY26/3 is ¥6.7B, with basic EPS of ¥38.17.
FX rate assumption for 2H FY26/3 is USD/JPY 130.0; full-year sensitivity is approx. ¥1.0B per ¥1 change in net sales.
Operating margin expected to recover in FY27/3 as product cost ratio improves and new mass production ramps up.
Latest events from Socionext
- Sales rebounded, but profits and margins remain pressured by costs and FX; guidance unchanged.6526
Q3 202630 Jan 2026 - Sharp profit and sales drop in 1Q FY26/3, but full-year guidance and recovery outlook are maintained.6526
Q1 202631 Jul 2025 - Sales and profit fell, but R&D and NRE revenue rose; treasury stock buyback approved.6526
Q2 202513 Jun 2025 - Net sales fell 14.1% but operating income and R&D investment both increased.6526
Q1 202513 Jun 2025 - Revenue and profit fell sharply, but investments and design wins support future growth.6526
Q4 20256 Jun 2025 - Net sales dropped 14.4% and the full-year outlook was cut amid weak China demand.6526
Q3 20255 Jun 2025